BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
Federal Trade Commission
Johnson and Johnson

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020195

« Back to Dashboard

NDA 020195 describes FENTANYL, which is a drug marketed by Cephalon, Abbott, Hospira, Watson Labs, Mallinckrodt, Par Pharm, Astrazeneca, Watson Labs Inc, West-ward Pharms Int, 3m Drug Delivery, Actavis Labs Ut Inc, Aveva, Lavipharm Labs, Mallinckrodt Inc, Mayne Pharma, Mylan Technologies, and Noven, and is included in twenty-three NDAs. Additional details are available on the FENTANYL profile page.

The generic ingredient in FENTANYL is fentanyl. There are thirty-one drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the fentanyl profile page.

Summary for 020195

Therapeutic Class:Analgesics
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 020195

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TROCHE/LOZENGE;ORALStrengthEQ 0.2MG BASE
Approval Date:Oct 4, 1993TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TROCHE/LOZENGE;ORALStrengthEQ 0.3MG BASE
Approval Date:Oct 4, 1993TE:RLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TROCHE/LOZENGE;ORALStrengthEQ 0.4MG BASE
Approval Date:Oct 4, 1993TE:RLD:No

Expired Orange Book Patents for NDA: 020195

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
CephalonFENTANYLfentanyl citrateTROCHE/LOZENGE;ORAL020195-001Oct 4, 1993► Subscribe► Subscribe
CephalonFENTANYLfentanyl citrateTROCHE/LOZENGE;ORAL020195-007Oct 30, 1995► Subscribe► Subscribe
CephalonFENTANYLfentanyl citrateTROCHE/LOZENGE;ORAL020195-003Oct 4, 1993► Subscribe► Subscribe
CephalonFENTANYLfentanyl citrateTROCHE/LOZENGE;ORAL020195-002Oct 4, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: